Key facts
- Kadence Bio’s last known valuation is $25.2M (Oct 2021).
- It has raised $16.3M; the latest was Early Stage VC ($10.0M) in Jul 2025.
- Notable investors include Endless Frontier Labs, Dhuna Ventures, UCEA Capital Partners, Apeiron Capital, Alexander Luik — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Kadence Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kadence Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kadence Bio
Developer of a small-molecule therapeutic designed to address significant unmet needs in sexual and mental well-being. The company offers a clinical-stage treatment for premature ejaculation, enabling men experiencing challenges with sexual performance, mental health, and relationship wellbeing to access the first FDA-approved therapeutic option.
- Sector
- Healthcare
- HQ
- Sevenoaks, United Kingdom
- Founded
- 2021
- Employees
- 18
- Website
- kadencebio.com/
- Ownership
- Privately Held (backing)
Kadence Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kadence Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kadence Bio in its N-PORT filings yet. We sweep new filings monthly.